Recent advances in the discovery of small molecule therapies for HCV

Current Opinion in Drug Discovery and Development

Volumn 4, Issue 4, 2001, Pages 411-416

  Myles, D C ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Helicase; Hepatitis C; IFN; IMPDH; IRES; Polymerase; Proteinase; Ribavirin; Sub genomic replicon

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HELICASE; HEPTAZYME; ISIS 14803; MERIMEPODIB; RIBAVIRIN; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VP 50406;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG SCREENING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; REVIEW; SIDE EFFECT; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 0034916847     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Novel approaches to the treatment of hepatitis C virus infection
2. Recent developments in hepatitis C antiviral research 1999-2000
3. Recent advances in prevention and treatment of hepatitis C virus infections
4. Combination treatment for chronic hepatitis C: What is the role of ribavirin?
5. Adverse effects and other safety aspects of the hepatitis C antivirals
6. Treatment options in patients with chronic hepatitis C
7. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
8. Emerging targets in the treatment of hepatitis C virus infection
9. Binding of hepatitis C virus to CD81
10. Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice
11. Hepatitis C viral IRES inhibition by phenazine and phenazine-like molecules
12. NS3-4A protease as a target for interfering with hepatitis C virus replication
13. Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain
14. Optimization of the P'-region of peptide inhibitors of hepatitis C virus NS3/4A protease
15. Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor
16. Broad spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with α-interferon